Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

@article{LeylandJones2005MaintainingNH,
  title={Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.},
  author={Brian R. Leyland-Jones and Vladimir Semiglazov and Marek Pawlicki and Tadeusz Pieńkowski and Sergei Alexeevich Tjulandin and George M. Manikhas and Antoly Makhson and Anton Roth and David Dodwell and Jos{\'e} Baselga and Mikhail Y. Biakhov and Konstantinas Povilas Valuckas and Edouard Voznyi and Xiangyang Liu and Els Vercammen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 25},
  pages={5960-72}
}
PURPOSE To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women with metastatic breast cancer (MBC) receiving first-line chemotherapy. PATIENTS AND METHODS Eligible patients were randomly assigned to receive epoetin alfa 40,000 U once weekly or placebo for 12 months. Study drug was initiated if baseline Hb was < or = 13 g/dL or when Hb decreased to < or = 13g/dL during the study. The primary… CONTINUE READING

From This Paper

Topics from this paper.
263 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 263 extracted citations

Similar Papers

Loading similar papers…